Clinical Trial Update: Study of BCMA CAR-T in Multiple Myeloma [EARLY_Phase 1]

View source ↗

Summary

An early-phase study of BCMA-targeted CAR-T cell therapy for relapsed and refractory multiple myeloma; status is currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BCMA CAR-T

Snippet

Sponsor: Allife Medical Science and Technology Co., Ltd. | Conditions: Relapsed and Refractory Multiple Myeloma | EARLY_Phase 1 | Status: UNKNOWN